{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03392467",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MP-CR-012"
      },
      "Organization": {
        "OrgFullName": "Medipost Co Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants",
      "OfficialTitle": "A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of PNEUMOSTEM for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia in Premature Infants"
    },
    "StatusModule": {
      "StatusVerifiedDate": "August 2020",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "August 13, 2018",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2021",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "July 2021",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "December 20, 2017",
      "StudyFirstSubmitQCDate": "January 2, 2018",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "January 8, 2018",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "August 26, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "August 28, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Medipost Co Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This study is to evaluate the efficacy and safety of PNEUMOSTEMÂ® for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia (Severe BPD) in Premature Infants. Half of subjects will receive PNEUMOSTEM, while the other half will receive a placebo.",
      "DetailedDescription": "Bronchopulmonary dysplasia (BPD) is a chronic lung disease in which premature infants and it results in significant morbidity and mortality. PNEUMOSTEM is intended to prevent and treat BPD by modulating inflammation and repairing damaged lung tissue in premature infants through paracrine effects."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Severe Bronchopulmonary Dysplasia"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Prevention",
        "DesignMaskingInfo": {
          "DesignMasking": "Quadruple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "60",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "PNEUMOSTEM",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "human umbilical cord blood derived mesenchymal stem cell (hUCB-MSC)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: PNEUMOSTEM"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "normal saline",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "PNEUMOSTEM",
            "InterventionDescription": "human umbilical cord blood-derived mesenchymal stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "PNEUMOSTEM"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Placebo",
            "InterventionDescription": "normal saline",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Percentage of subjects who have severe BPD or are dead",
            "PrimaryOutcomeDescription": "Percentage of subjects who have severe BPD or are dead",
            "PrimaryOutcomeTimeFrame": "36 weeks postmenstrual age (PMA)"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Percentage of subjects who have moderate/severe BPD or are dead",
            "SecondaryOutcomeDescription": "Percentage of subjects who have moderate/severe BPD or are dead",
            "SecondaryOutcomeTimeFrame": "36 weeks PMA"
          },
          {
            "SecondaryOutcomeMeasure": "Percentage of subjects by severity of BPD",
            "SecondaryOutcomeDescription": "Percentage of subjects by severity of BPD",
            "SecondaryOutcomeTimeFrame": "prenatal 28 days/36 weeks PMA"
          },
          {
            "SecondaryOutcomeMeasure": "Percentage of subjects in death due to lung disease",
            "SecondaryOutcomeDescription": "Percentage of subjects in death due to lung disease",
            "SecondaryOutcomeTimeFrame": "prenatal 28 days/36 weeks PMA and study end timepoint"
          },
          {
            "SecondaryOutcomeMeasure": "intubation duration",
            "SecondaryOutcomeDescription": "intubation duration",
            "SecondaryOutcomeTimeFrame": "up to 24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "ventilation duration",
            "SecondaryOutcomeDescription": "ventilation duration",
            "SecondaryOutcomeTimeFrame": "up to 24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "continuous positive airway pressure (CPAP) treatment duration",
            "SecondaryOutcomeDescription": "continuous positive airway pressure (CPAP) treatment duration",
            "SecondaryOutcomeTimeFrame": "up to 24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "treatment duration with supplemental oxygen",
            "SecondaryOutcomeDescription": "treatment duration with supplemental oxygen",
            "SecondaryOutcomeTimeFrame": "up to 24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "% of subjects treated with steroid for weaning ventilator",
            "SecondaryOutcomeDescription": "% of subjects treated with steroid for weaning ventilator",
            "SecondaryOutcomeTimeFrame": "up to 24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Retinopathy of prematurity (ROP) with stage III or higher",
            "SecondaryOutcomeDescription": "number of subjects with ROP with stage III or higher",
            "SecondaryOutcomeTimeFrame": "up to 24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "number of subjects with retinopathy of prematurity that needs bevacizumab or laser therapy",
            "SecondaryOutcomeDescription": "number of subjects with retinopathy of prematurity that needs bevacizumab or laser therapy",
            "SecondaryOutcomeTimeFrame": "up to 24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "z-score",
            "SecondaryOutcomeDescription": "percentile for body weight, height, and head circumference",
            "SecondaryOutcomeTimeFrame": "up to 24 weeks (visit 10)"
          },
          {
            "SecondaryOutcomeMeasure": "days in hospitalization",
            "SecondaryOutcomeDescription": "days in hospitalization",
            "SecondaryOutcomeTimeFrame": "up to 24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "changes in tracheal suction fluid examination",
            "SecondaryOutcomeDescription": "changes in tracheal suction fluid examination",
            "SecondaryOutcomeTimeFrame": "from screening to 7 days after IP administration (visit 5)"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nat screening and randomization\n\n23 weeks to < 25 weeks of gestational age\n500g to 1,250g body weight at birth\npremature infant within postnatal 13 days of age\nuse ventilator with ventilation rate >12 breaths/min or oxygen supply > 25%, or use high frequency ventilator (HFV)\n\nat IP administration\n\npremature infant within postnatal 5 to 14 days of age\nNo improvement in ventilator setting 24 hours prior to administration of IP\n\nExclusion Criteria:\n\nsubject with cyanotic congenital heart disease or non-cyanotic congenital heart disease that can cause heart failure\nsubject with pulmonary hypoplasia, congenital diaphragmatic hernia, or serious lung malformation such as congenital cystic lung disease\nsubject with chromosome disorder with serious malformation (i.e. Edward syndrome, patau syndrome, Down syndrome, etc.), severe congenital malformation (i.e. hydrocephalus, encephalocele, etc.), or severe congenital infection (i.e., herpes, toxoplasmosis, rubella, syphilis, AIDS, etc.)\nsubject with serious sepsis as active infection or shock due to sepsis\nsubject with grade 3 or 4 of bilateral intraventricular hemorrhage\nat screening, subject with active pulmonary hemorrhage or active air leak syndrome\nsubject who underwent/will undergo surgery within 72 hours before/after investigational product (IP) administration\nsubject who is expected to be treated with surfactant within 24 hours prior to IP administration\nsubject who is expected to be allergic to gentamicin (Birth mother's allergy for gentamicin will be confirmed).\nsubject who have previously participated in other clinical trials\nsubject who is considered ineligible by investigator due to other medical reasons",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MaximumAge": "13 Days",
      "StdAgeList": {
        "StdAge": [
          "Child"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Eunyoung Lee",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "82234656748",
            "CentralContactEMail": "ley0113@medi-post.co.kr"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Wonsoon Park",
            "OverallOfficialAffiliation": "Samsung Medical Center",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Airhan Kim",
            "OverallOfficialAffiliation": "Asan Medical Center",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Asan medical Center",
            "LocationStatus": "Recruiting",
            "LocationCity": "Seoul",
            "LocationCountry": "Korea, Republic of",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Airhan Kim, MD",
                  "LocationContactRole": "Contact"
                },
                {
                  "LocationContactName": "Airhan Kim, MD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          },
          {
            "LocationFacility": "Samsung Medical Center",
            "LocationStatus": "Recruiting",
            "LocationCity": "Seoul",
            "LocationCountry": "Korea, Republic of",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Wonsoon Park, MD",
                  "LocationContactRole": "Contact"
                },
                {
                  "LocationContactName": "Wonsoon Park, MD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "33876883",
            "ReferenceType": "derived",
            "ReferenceCitation": "Ahn SY, Chang YS, Lee MH, Sung SI, Lee BS, Kim KS, Kim AR, Park WS. Stem cells for bronchopulmonary dysplasia in preterm infants: A randomized controlled phase II trial. Stem Cells Transl Med. 2021 Aug;10(8):1129-1137. doi: 10.1002/sctm.20-0330. Epub 2021 Apr 20."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000001997",
            "ConditionMeshTerm": "Bronchopulmonary Dysplasia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000055397",
            "ConditionAncestorTerm": "Ventilator-Induced Lung Injury"
          },
          {
            "ConditionAncestorId": "D000055370",
            "ConditionAncestorTerm": "Lung Injury"
          },
          {
            "ConditionAncestorId": "D000008171",
            "ConditionAncestorTerm": "Lung Diseases"
          },
          {
            "ConditionAncestorId": "D000012140",
            "ConditionAncestorTerm": "Respiratory Tract Diseases"
          },
          {
            "ConditionAncestorId": "D000007235",
            "ConditionAncestorTerm": "Infant, Premature, Diseases"
          },
          {
            "ConditionAncestorId": "D000007232",
            "ConditionAncestorTerm": "Infant, Newborn, Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M25022",
            "ConditionBrowseLeafName": "Premature Birth",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4425",
            "ConditionBrowseLeafName": "Bronchopulmonary Dysplasia",
            "ConditionBrowseLeafAsFound": "Bronchopulmonary Dysplasia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M27296",
            "ConditionBrowseLeafName": "Lung Injury",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M27305",
            "ConditionBrowseLeafName": "Ventilator-Induced Lung Injury",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10320",
            "ConditionBrowseLeafName": "Lung Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14129",
            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9431",
            "ConditionBrowseLeafName": "Infant, Premature, Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9428",
            "ConditionBrowseLeafName": "Infant, Newborn, Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T874",
            "ConditionBrowseLeafName": "Bronchopulmonary Dysplasia",
            "ConditionBrowseLeafAsFound": "Bronchopulmonary Dysplasia",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC16",
            "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC26",
            "ConditionBrowseBranchName": "Wounds and Injuries"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}